(R)-哌啶-3-醇 | 62414-68-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (R)-哌啶-3-醇
• 中文别名: (R)-3-哌啶醇
• 英文名称: (3R)-piperidin-3-ol
• 英文别名: (R)-piperidin-3-ol；(R)-(+)-3-hydroxypiperidine
• CAS: 62414-68-0
• 化学式: C₅H₁₁NO
• 分子量: 101.148
• InChiKey: BIWOSRSKDCZIFM-RXMQYKEDSA-N

物化性质

• 熔点：
  91-92℃
• 沸点：
  191.9±23.0 °C(Predicted)
• 密度：
  1.016±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  3263
• 危险性描述：
  H314
• 储存条件：
  存储条件：2-8°C，避光干燥。

反应信息

• 作为反应物：
  描述：

  (R)-哌啶-3-醇 在 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 7.0h， 生成 benidipine
  参考文献：
  名称：

  Muto; Kuroda; Kawato, Arzneimittel-Forschung/Drug Research, 1988, vol. 38, # 11 A, p. 1662 - 1665

  摘要：

  DOI：
• 作为产物：
  描述：

  N-benzyl-(S)-proline methyl ester 在 lithium aluminium tetrahydride 、 10% palladium on activated charcoal 、 氢气 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 乙醇 为溶剂， -78.0~20.0 ℃ 、101.33 kPa 条件下， 反应 141.66h， 生成 (R)-哌啶-3-醇
  参考文献：
  名称：

  The synthesis of piperidine nucleoside analogs—a comparison of several methods to access the introduction of nucleobases

  摘要：

  This work deals with the synthesis of piperidine and hydroxypiperidine analogs of nucleosides. Starting from commercially available 3-hydroxypiperidine, proline or 4-hydroxyproline, a series of piperidine derivatives of both purine and pyrimidine nucleobases was prepared. Various methods of nucleobase attachment were evaluated. The prepared compounds were tested for cytostatic, antibacterial, and antiviral properties but no significant activity was found. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.12.029

文献信息

• PIPERIDINE DERIVATIVES FOR GPR119 AGONIST
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP.

  公开号：US20150166480A1

  公开（公告）日：2015-06-18

  The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

  本发明涉及新型的哌啶衍生物、它们的立体异构体或药用可接受的盐；制备该化合物的方法；以及包含该化合物的药物组合物。根据本发明，具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢紊乱，包括糖尿病（尤其是II型）及相关疾病。
• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• 1,2-Di(cyclic)substituted benzene compounds
  申请人：Kawahara Tetsuya

  公开号：US20050261291A1

  公开（公告）日：2005-11-24

  In one aspect, the present invention provides compounds having formula (1) or (100), a salt thereof or a hydrate of the foregoing, which compounds exhibit excellent cell adhesion inhibitory action or cell infiltration inhibitory action, and are useful as therapeutic or prophylactic agents for various inflammatory diseases and autoimmune diseases associated with adhesion and infiltration of leukocytes, such as inflammatory bowel disease (particularly ulcerative colitis or Crohn's disease), irritable bowel syndrome; rheumatoid arthritis, psoriasis, multiple sclerosis, asthma and atopic dermatitis. wherein R10 represents optionally substituted cycloalkyl, etc., R20-23 represent hydrogen, alkyl, alkoxy, etc., R30-32 represent hydrogen, alkyl, oxo, etc., and R40 represents optionally substituted alkyl, etc.

  在一个方面，本发明提供具有式（1）或（100）的化合物，其盐或前述的水合物，这些化合物表现出优异的细胞粘附抑制作用或细胞浸润抑制作用，并且可用作治疗或预防与白细胞粘附和浸润相关的各种炎症性疾病和自身免疫疾病的药物，例如炎症性肠病（尤其是溃疡性结肠炎或克罗恩病）、肠易激综合征；类风湿性关节炎、牛皮癣、多发性硬化、哮喘和特应性皮炎。 其中R10代表可选择地取代的环烷基等，R20-23代表氢、烷基、烷氧基等，R30-32代表氢、烷基、氧代基等，R40代表可选择地取代的烷基等。
• New Esters of 4-Amino-5-chloro-2-methoxybenzoic Acid as Potent Agonists and Antagonists for 5-HT₄ Receptors
  作者：Donglai Yang、Jean-Louis Soulier、Sames Sicsic、Monique Mathé-Allainmat、Béatrice Brémont、Tiziano Croci、Rosanna Cardamone、Giulio Aureggi、Michel Langlois

  DOI：10.1021/jm960320m

  日期：1997.2.1

  hoxybenzoic acid and substituted 1-piperidineethanol were synthesized and found to be potent 5-HT4 receptor agonists in the electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum and the rat esophagus muscle. Monosubstitution of the piperidine ring with Me, OH, NH-Ac, or CONH2 groups gave compounds equipotent to 7a (ML 10302), a 5-HT4 receptor agonist previously reported

  合成了许多衍生自4-氨基-5-氯-2-甲氧基苯甲酸和取代的1-哌啶乙醇的苯甲酸酯，它们在豚鼠回肠的电刺激的肠神经丛和纵肌中是有效的5-HT4受体激动剂。和大鼠食道肌肉。哌啶环被Me，OH，NH-Ac或CONH2基团单取代后，化合物等效于7a（ML 10302），这是先前报道的具有纳摩尔摩尔亲和力的5-HT4受体激动剂。7a，k与5-羟色胺（5-HT）一样有效，但最大响应仅为5-HT的60-80％，表明这些化合物具有部分激动剂特性。在大鼠纹状体中用[3H] GR 113808进行结合测定，发现其中一些化合物对5-HT4受体具有纳摩尔摩尔亲和力（7a，Ki = 1.07 +/- 0.5 nM； 7k，Ki = 1。0 +/- 0.3 nM）。在哌啶环上引入两个甲基导致2-[（（顺式和反式-3,5-二甲基哌啶基）乙基] -4-氨基-5-氯-2-甲氧基苯甲酸酯）的药理学特性发生了显着变化， 7克，小时
• [EN] PIPERIDINE DERIVATIVES FOR GPR119 AGONIST<br/>[FR] DÉRIVÉS DE PIPÉRIDINE AGONISTES DE GPR119
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2013187646A1

  公开（公告）日：2013-12-19

  The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

  本发明涉及新型哌啶衍生物，其立体异构体或其药学上可接受的盐；制备该化合物的方法；以及包含该化合物的药物组合物。根据本发明，具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢性疾病，包括糖尿病（特别是II型）及相关疾病。